AliveDx Suisse S.A. and Axon Lab AG have signed a distribution agreement, which will enable Axon Lab to distribute the MosaiQ® solution in Austria, Germany and Switzerland. The distribution agreement takes effect immediately.
AliveDx is dedicated to expanding its reach and presence across various regions and to creating clinical and economical value for clinicians, helping them to shorten the time to diagnosis. This strategic collaboration with an important partner in Austria, Switzerland, and Germany, Europe’s largest IVD market, is a testimony to the company’s commitment to supporting the healthcare sector and enhancing patient care.
The MosaiQ platform simplifies workflows and creates efficiencies thanks to its multiplexing microarray assay technology. This streamlined and efficient approach offers faster and more cost-effective solutions to healthcare providers and patients alike.
“We are proud to announce this partnership with another key player in the European market. We look forward to working with Axon Lab AG and playing a strategic role in improving patients’ lives in the region,” said Manuel O. Méndez, AliveDx’s CEO.
Axon Lab AG is a Pan-European distributor and manufacturer with over 30 years of experience in the In-Vitro Diagnostics, Medical IT, and Life Science sectors. The company offers high-level expertise across the entire service chain, logistics, personal support, leading digital expertise, training concepts, and in-house research and development.
“This strategic partnership with AliveDx demonstrates our commitment to serving a demanding market with the latest technological developments in Autoimmunity testing technology. We are thrilled to broaden our highly specialized portfolio with this state-of-the-art autoimmunity testing solution,” said Lukas R. Hadorn, Axon Lab’s CEO.
To learn more, please visit the www.axonlab.com website.
